Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04854551 · ClinicalTrials.gov registry record · Phase 1
Opioid Modulation and Neural Reward Activation in Healthy Adults
A Phase 1 study of Alcohol Drinking and Opioid Use, Unspecified, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT04854551: Completed Phase 1 study of Alcohol Drinking and Opioid Use, Unspecified, sponsored by University of Colorado, Denver.
NCT04854551 is a Phase 1 study of Alcohol Drinking and Opioid Use, Unspecified that has completed, run by University of Colorado, Denver. The registered enrollment target is 13 participants, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04854551, a Phase 1 study of Alcohol Drinking and Opioid Use, Unspecified, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double blind study of the effects of opioid antagonism on the brain's reward response. The investigators will recruit participants to undergo two scans, one on active medication and one on placebo. During the scan, the investigators will assess reward.
Primary Outcome
Percent signal change relative to baseline in the nucleus accumbens during cue to win $5 as assessed during functional MRI. Higher values of percent signal change indicate greater activation to reward. We will compare the active medication condition to the placebo, establishing whether there is a difference between the conditions.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Naltrexone
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 1 |
What the finished NCT04854551 record still lists
NCT04854551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Alcohol Drinking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04854551 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT04854551 about?
NCT04854551 is a clinical study titled "Opioid Modulation and Neural Reward Activation in Healthy Adults". This is a double blind study of the effects of opioid antagonism on the brain's reward response. The investigators will recruit participants to undergo two scans, one on active medication and one on placebo. During the scan, the investigators will assess reward.
What is the current status of trial NCT04854551?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-05-01. Estimated completion is 2022-04-18.
What conditions does trial NCT04854551 study?
This clinical trial studies the following conditions: Alcohol Drinking, Opioid Use, Unspecified.
What interventions are being tested in trial NCT04854551?
The interventions under investigation include: Placebo (OTHER), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT04854551?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04854551 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Drinking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04854551's enrollment target sits among peer trials
13 82nd of 85 higher than 4 of 85 other Alcohol Drinking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Drinking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinic Receptor Genetic Variation and Alcohol Reward
RECRUITING · Phase 1
-
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
RECRUITING · Phase 1
-
A Novel Compound for Alcoholism Treatment
COMPLETED · Phase 1
-
Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
COMPLETED · Phase 1
-
The Behavioral Effects of Opioids and Alcohol
COMPLETED · Phase 1
-
Alcohol and "Heat of the Moment" Sexual Decision Making
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI